From Agios to Deciphera, Steve Hoerter plots another oncology launch; Roche exec Christiane Hamachar moves to India as CEO of Biocon Biologics
? Deciphera $DCPH has scooped Agios? chief commercial officer Steve Hoerter to fill retiring CEO Michael Taylor?s shoes. The Waltham, MA-based biotech is placing its trust in Hoerter?s sales acumen, especially for cancer drugs, acquired throughout his career at companies like Clovis, Roche, Genentech, Chiron, and Eli Lilly. The first;
- → Deciphera $DCPH has scooped Agios’ chief commercial officer Steve Hoerter to fill retiring CEO Michael Taylor’s shoes.
- The Waltham, MA-based biotech is placing its trust in Hoerter’s sales acumen, especially for cancer drugs, acquired throughout his career at companies like Clovis, Roche, Genentech, Chiron, and Eli Lilly.
- → Japan’s Sumitomo Dainippon Pharma has tapped clinical development chief Antony Loebel to helm its Marlborough, MA-based subsidiary Sunovion.
- Riva will be CEO of the subsidiary company, which will have its own board and be heavily focused on oncology and T cells, with “five clinical and three preclinical assets in development, three clinical assets currently in Phase 2b, and one asset likely to enter Phase 2b in FY20.
- Engineered to deliver alpha particles to cancer cells, its lead drug, FPI-1434, consists of an antibody directed toward the insulin-like growth factor-1 receptor 1 (IGF-1R) and an actinium-225.